Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has revealed that all patients have been dosed in a Phase I clinical study for its siRNA drug candidate STP707, which targets multiple solid tumors. The study is designed to assess the safety, tolerability, and anti-tumor activity of STP707 in six dose escalation cohorts via intravenous administration.
Basket Trial Design and Patient Enrollment
The basket trial enrolled 50 patients with advanced solid tumors, including pancreatic cancer, liver cancer, colon cancer, and melanoma, who had failed to respond to standard therapy. The results indicate that the intravenous infusion of STP707, administered four times a month using a dose escalation method, was safe across all groups, with no dose limiting toxicity identified.
Positive Therapeutic Efficacy Signs
The study showed strongly positive signs of therapeutic efficacy, with 74% of patients achieving optimal response for disease stability, and several patients experiencing reduced tumor burden. The clinical research duration is approximately 77 days, providing a comprehensive assessment of STP707’s potential in treating solid tumors.
STP707’s Composition and Mechanism
STP707 is composed of two siRNA oligonucleotides targeting TGF-β1 and COX-2 mRNA, combined with a histidine-lysine copolypeptide (HKP+H) carrier to formulate a nanoparticle formulation. Utilizing dual-targeted inhibitory properties and Sirnaomics’ proprietary PNP delivery technology, STP707 enhances the targeted delivery of drugs to solid and metastatic tumors through systemic administration, while inhibiting the expression of TGF-β1 and COX-2. Preclinical studies have demonstrated that simultaneous knockdown of TGF-β1 and COX-2 in the tumor microenvironment enhances T cell infiltration. Combination studies have shown that the combination of STP707 and PD-L1 antibody has synergistic antitumor activity in an orthotopic mouse liver cancer model.-Fineline Info & Tech
